Recently, the SAVOR TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus--Thrombolysis in Myocardial Infarction-53) reported a significant increase in the risk of hospitalizations for heart failure in patients treated with saxagliptin in comparison with placebo. Aim of the present meta-analysis is the systematic collection and synthesis of information on treatment-emergent cases of acute heart failure described in randomized clinical trials with DPP4.
Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials / Monami, M; Dicembrini, I; Mannucci, E. - In: NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES. - ISSN 1590-3729. - STAMPA. - 24:(2014), pp. 689-697. [10.1016/j.numecd.2014.01.017]
Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials
DICEMBRINI, ILARIA;MANNUCCI, EDOARDO
2014
Abstract
Recently, the SAVOR TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus--Thrombolysis in Myocardial Infarction-53) reported a significant increase in the risk of hospitalizations for heart failure in patients treated with saxagliptin in comparison with placebo. Aim of the present meta-analysis is the systematic collection and synthesis of information on treatment-emergent cases of acute heart failure described in randomized clinical trials with DPP4.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2014_Monami_NMCD_DPP4&HF.pdf
Accesso chiuso
Tipologia:
Versione finale referata (Postprint, Accepted manuscript)
Licenza:
Tutti i diritti riservati
Dimensione
976.75 kB
Formato
Adobe PDF
|
976.75 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
